FDG positron emission tomography in melanoma.
D054598:Blue Cross Blue Shield Insurance Plans; D018795:Device Approval; D017277:Drug Approval; D005069:Evaluation Studies as Topic; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008545:Melanoma / Q000000981:diagnostic imaging*; D017063:Outcome Assessment, Health Care; D019275:Radiopharmaceuticals; D013673:Technology Assessment, Biomedical; D014055:Tomography, Emission-Computed / Q000379:methods; D014481:United States; D014486:United States Food and Drug Administration
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18